Blog
RSS FeedPosted by Michael Wonder on 26 Mar 2026
UCB receives positive CHMP opinion for new Zilbrysq (zilucoplan) pre-filled pen in EU for adults living with generalised myasthenia gravis
26 March 2026 - UCB today announced that the CHMP of the EMA has issued a positive opinion recommending a ...
Posted by Michael Wonder on 25 Mar 2026
ICER launches program to accelerate the consideration of value into drug development programs
25 March 2026 - ICER will leverage its health technology assessment expertise to encourage better evidence development in clinical trial ...
Posted by Michael Wonder on 25 Mar 2026
Agenda for the July 2026 PBAC meeting (25 March 2026)
25 March 2026 - The agenda for the July 2026 PBAC meeting is now available. ...
Posted by Michael Wonder on 23 Mar 2026
EMA publishes agenda for 23-26 March 2026 CHMP meeting
23 March 2026 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 20 Mar 2026
NHS spending watchdog to review evidence on Alzheimer’s treatments
20 March 2026 - England’s drugs costs watchdog is to look again at whether new treatments for Alzheimer’s disease should ...
Posted by Michael Wonder on 20 Mar 2026
Public summary documents (first time decisions not to recommend and deferrals) – November 2025 PBAC meeting
20 March 2026 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the November 2025 PBAC ...
Posted by Michael Wonder on 12 Mar 2026
ICER releases draft evidence report on treatment for narcolepsy
12 March 2026 - Public comment period now open until 7 April 2026; requests to make oral comment during public ...
Posted by Michael Wonder on 12 Mar 2026
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
11 March 2026 - A new treatment option for menopausal hot flushes and night sweats can be used in the NHS ...
Posted by Michael Wonder on 09 Mar 2026
ICER to assess treatment for Parkinson’s disease
9 March 2026 - Report will be subject of CTAF meeting in October 2026; draft scoping document open to public ...
Posted by Michael Wonder on 06 Mar 2026
Public summary documents – November 2025 PBAC meeting
6 March 2026 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2025 PBAC ...
Posted by Michael Wonder on 06 Mar 2026
Agenda for the March 2026 PBAC meeting (4 March 2026)
6 March 2026 - The Department of Health has published an updated agenda for the March 2026 PBAC agenda (version ...
Posted by Michael Wonder on 06 Mar 2026
Roche's Columvi, Takeda's Fruzaqla pass first review for Korea insurance coverage
5 March 2026 - Roche's DLBCL treatment Columvi (glofitamab) and Takeda's metastatic colorectal cancer treatment Fruzaqla (fruquintinib) have cleared the ...
Posted by Michael Wonder on 04 Mar 2026
Problems in study implementation: It often affects patient reported outcomes.
2 March 2026 - Patient-reported outcomes are of great importance for the evaluation of new drugs. However, these outcomes are repeatedly ...
Posted by Michael Wonder on 03 Mar 2026
Alnylam receives positive recommendation from Canada's Drug Agency for the public reimbursement of Amvuttra (vutrisiran injection), the first and only RNAi therapeutic for the treatment of cardiomyopathy in adult patients with ATTR amyloidosis
2 March 2026 - Alnylam Canada is pleased to announce it has received a positive recommendation from Canada's Drug Agency for ...
Posted by Michael Wonder on 01 Mar 2026
EMA CHMP recommends EU approval of Henlius’ pertuzumab biosimilar HLX11
27 February 2026 - Shanghai Henlius Biotech announced that the CHMP of the EMA has adopted a positive opinion recommending the ...